Trials / Active Not Recruiting
Active Not RecruitingNCT06334432
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
A Phase 1/2, First-in-Human, Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 466 (estimated)
- Sponsor
- Nuvation Bio Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
- HER2-negative Breast Cancer
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Pancreatic Cancer
- Platinum-resistant Ovarian Cancer (PROC)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NUV-1511 | Novel small molecule |
Timeline
- Start date
- 2024-03-14
- Primary completion
- 2027-03-01
- Completion
- 2027-10-01
- First posted
- 2024-03-28
- Last updated
- 2026-01-14
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06334432. Inclusion in this directory is not an endorsement.